risdiplam (Evrysdi) Report issue

Small molecule Orphan Drug FDA Approved FDA Fast Track FDA Priority Review FDA

Active Ingredient History

NOW
  • Now
Risdiplam, sold under the brand name Evrysdi, is a medication used to treat spinal muscular atrophy (SMA) and the first oral medication approved to treat this disease.   Wikipedia

More Chemistry

Drug Pricing (per unit)

United States

$105.3193 - $137.8850
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

ro7034067

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue